5th Annual Symposium

The Next Frontier: Combination Therapy in Inflammatory Bowel Disease

Register Today
Event Date
When

Friday, May 17, 2024
(8:15 AM EST – 4:00 PM EST)

Event Details

Experience in-person presentations by our expert presenters and join interactive working sessions.

Alimentiv Translational Research Consortium presents:
The Next Frontier: Combination Therapy in Inflammatory Bowel Disease

Event Overview:

This full-day, educational event is organized for and by members of the Alimentiv Translational Research Consortium (ATRC) to understand the role of combination therapies in IBD and what can be learned from other indications who were early adopters of combination therapy.

The Symposium will bring together key stakeholders including gastroenterologists, basic & translational scientists, clinical pharmacologists, trialists and industry sponsors.

Location: The Westin Washington, D.C. City Center
Address: 1400 M Street NW, Washington, DC, USA, 20005
Symposium: Friday, May 17, 2024 (8:15 AM – 4:00 PM EST)
Reception: Immediately following the symposium

Expert Panel

Jean-Frederic Colombel, MD
Jean-Frederic Colombel, MD
(Icahn School of Medicine at Mount Sinai, USA)

Arthur Kavanaugh, MD
Arthur Kavanaugh, MD
(University of California San Diego, USA)

Bruce Sands, MD, MS
Bruce Sands, MD, MS
(Icahn School of Medicine at Mount Sinai, USA)

Jackie Benson, PhD
Jackie Benson, PhD
(Sorriso Pharmaceuticals, USA)

Saurabh Mehandru, MD
Saurabh Mehandru, MD
(Icahn School of Medicine at Mount Sinai, USA)

TBD
TBD
(TBD)

Agenda

7:45 AM EST Registration & Continental Breakfast
8:15 AM EST Welcome & Introductions
Session 1: Clinical Efficacy and Safety on Combination Therapy
Chair: Vipul Jairath MBChB, DPhil, MRCP, FRCPC (Western University/Alimentiv)
8:30 AM State of the art: Combination Therapy in IBD - how did we get here and where are we going

Jean-Frederic Colombel, MD (Icahn School of Medicine at Mount Sinai, USA)

9:00 AM State of the art: Combination Therapy in Rheumatology - how did we get here and where are we going

Arthur Kavanaugh, MD (University of California San Diego, USA)

9:30 AM Panel discussion
9:55 AM Break
Session 2: Clinical Pharmacology & Translational Medicine of Combination Therapy
Chair: Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai, USA)
10:15 AM Impact of combination therapy on mucosal and systemic immune system

TBD

10:40 AM Mechanistic vs. opportunistic approach to combination therapies

Saurabh Mehandru, MD (Icahn School of Medicine at Mount Sinai, USA)

11:05 AM Additivity vs. synergy: hedging bets when picking combinations in rheumatology

TBD

11:30 AM Panel Discussion
11:55 AM Lunch
Session 3: Drug Design & Development
Chair: Vipul Jairath MBChB, DPhil, MRCP, FRCPC (Western University/Alimentiv)
12:55 PM Challenges and opportunities when developing bi-specific antibodies or antibody constructs

Jackie Benson, PhD (Sorriso Pharmaceuticals, USA)

1:20 PM Clinical trial design considerations when testing combination therapies

Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai, USA)

1:45 PM Panel discussion
2:10 PM Break
Session 4: Breakout Session
Chair: Niels Vande Casteele, PharmD, PhD (UC San Diego / Alimentiv & AcelaBio, USA)
2:25 PM Instructions for breakout groups
2:30 PM Breakout groups
3:10 PM Breakout group presentations & general discussion
3:50 PM Summary and wrap-up
4:00 PM Adjourn & reception to follow

Organizing Committee